Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.8%

17 terminated/withdrawn out of 59 trials

Success Rate

41.4%

-45.1% vs industry average

Late-Stage Pipeline

4 trials in Phase 3/4

Results Transparency

92%

11 of 12 completed trials have results

Key Signals

19 recruiting11 with results9 terminated8 withdrawn

Enrollment Performance

Analytics

N/A

22(45.8%)

Phase 2

13(27.1%)

Phase 1

9(18.8%)

Phase 3

2(4.2%)

Phase 4

2(4.2%)

48Total

N/A(22)

Phase 2(13)

Phase 1(9)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (59)

Showing 20 of 59 trials

NCT04689048Phase 1Recruiting

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Role: lead

NCT07506018Not ApplicableRecruiting

MucoLock™ for Treatment of Stomatitis

Role: lead

NCT07455903Phase 2Not Yet Recruiting

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Role: lead

NCT07454668Phase 1Not Yet Recruiting

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Role: lead

NCT05425004Phase 2Recruiting

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Role: lead

NCT07136350Not ApplicableEnrolling By Invitation

Nurse Caring Communication Engagement

Role: lead

NCT05789589Phase 1Recruiting

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Role: lead

NCT07222839Not ApplicableEnrolling By Invitation

Impact of Immersive Video Education on Cardiothoracic Surgery Anxiety and Outcomes

Role: lead

NCT05681195Phase 2Recruiting

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Role: lead

NCT05504681Recruiting

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

Role: lead

NCT05534321Phase 1Recruiting

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

Role: lead

NCT06397573Not ApplicableActive Not Recruiting

Ablative Stereotactic MR-Guided Adaptive Reirradiation

Role: lead

NCT05756985Recruiting

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Role: lead

NCT05679674Not ApplicableRecruiting

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Role: lead

NCT06910241Phase 3Recruiting

Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs

Role: collaborator

NCT05553522Phase 1Terminated

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Role: lead

NCT06991101Phase 2Recruiting

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Role: lead

NCT07155876Not ApplicableEnrolling By Invitation

Exploring the Effect of Aromatherapy

Role: lead

NCT05554302Phase 2Recruiting

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Role: lead

NCT04802603Not ApplicableRecruiting

Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column

Role: lead